Transfemoral Versus Transradial Partial Splenic Artery Embolization in Patients With Hypersplenism

Hypersplenism Clinical Trial

Official title: Transfemoral Versus Transradial Partial Splenic Artery Embolization in Patients With Hypersplenism, a Randomized Controlled Trial

Status Completed

Clinical Trial Summary

The present study aimes at comparing the transradial and transfemoral approaches for partial splenic embolization in patients with hypersplenism.

Clinical Trial Description

Since its development in 1979, partial splenic embolization (PSE) has been universally accepted to treat patients with hypersplenism in preference to surgical splenectomy. The spleen is the primary source of antibodies, lymphocyte production, and responsible for phagocytosis of white cells. Additionally, it plays an essential role in the immune system. Unlike splenectomy, partial splenic embolization (PSE) maintained partial splenic function and was thought to be an effective alternative to treat thrombocytopenia and leukopenia resulted from hypersplenism with fewer complications. PSE is usually performed using a femoral artery approach that requires bed rest for a few hours. Recently, the transradial approach, with less obvious need for bed rest, has been more widely applied for cardiovascular intervention. ;

Related Conditions & MeSH terms

• Hypersplenism

• NCT number: NCT05446116
• Study type: Interventional
• Source: Zagazig University
• Status: Completed
• Phase: N/A
• Start date: June 1, 2019
• Completion date: October 18, 2021